Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Avistone Biotechnology’s Andatinib Receives China Conditional Approval for EGFR Ex20ins NSCLC

Fineline Cube Apr 30, 2026
Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Fineline Cube Apr 30, 2026
Company Deals

Hubei Guangji Pharmaceutical Expands Ex-Hospital Market Presence with New Partnerships

Fineline Cube Nov 26, 2024

China-based Hubei Guangji Pharmaceutical Co., Ltd. (SHE: 000952) is poised to establish a strong presence...

Company Drug

GeneQuantum Healthcare’s GQ1011 (AMB302) Receives FDA Approval for Clinical Study

Fineline Cube Nov 26, 2024

China-based GeneQuantum Healthcare, a leading developer of antibody drug conjugates (ADCs), has announced that it...

Company Deals

E-nitiate Biopharmaceuticals Strikes Licensing Deal with Joincare for QY101 Inhaler Rights

Fineline Cube Nov 26, 2024

China-based E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd, a joint venture between VivaVision Biotech and Betta Pharmaceuticals...

Company Deals

Luye Pharma’s Subsidiary Boan Biotech Strikes Licensing Deal for Biosimilars in Brazil

Fineline Cube Nov 25, 2024

China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd (HKG: 6955),...

Company Deals

Dizal Pharmaceutical Co., Ltd Scales Back Private Placement Fundraising to USD 255.1 Million

Fineline Cube Nov 25, 2024

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced revisions to its private placement plan,...

Company

Danish Pharma H. Lundbeck A/S Sees Strong Q3 and Q1-Q3 2024 Financial Results

Fineline Cube Nov 25, 2024

Denmark-based pharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF) has revealed its financial results for the...

Policy / Regulatory

National Allied Procurement Office Announces Round 10 VBP Tender Program with New Rules

Fineline Cube Nov 25, 2024

The National Allied Procurement Office has released a notification regarding Round 10 of the national...

Policy / Regulatory

Jiangsu Chia Tai Fenghai’s ALS Treatment FHND1002 Selected for CDE’s Patient-Centered Care Plan

Fineline Cube Nov 25, 2024

China’s Center for Drug Evaluation (CDE) has announced its intention to include Jiangsu Chia Tai...

Company Medical Device

Acotec Scientific Holdings Receives NMPA Approval for Thrombus Aspiration Catheter Support Tube

Fineline Cube Nov 25, 2024

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received marketing approval...

Company Drug

Henlius Biotech Initiates Phase III Study for HLX22 in Gastric Cancer Treatment

Fineline Cube Nov 25, 2024

Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced the dosing of the first patient...

Policy / Regulatory

China’s NHC Sets Sights on Enhancing Grassroots Drug Management and Access

Fineline Cube Nov 25, 2024

The National Health Commission (NHC) has issued a set of opinions designed to accelerate the...

Company Drug

MicroPort Scientific Corp.’s BonaFire Receives NMPA Approval as First Whole-Body MRI Safety Pacing Electrode Lead

Fineline Cube Nov 25, 2024

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced that it has received...

Company Drug

Base Therapeutics’ NK510 Receives US FDA Clearance for Advanced Solid Tumor Studies

Fineline Cube Nov 25, 2024

Shanghai-based cell therapy specialist Base Therapeutics has achieved clearance from the US Food and Drug...

Company Deals

Merck KGaA Partners with NTU Singapore to Drive Digital Transformation with Trust Technology

Fineline Cube Nov 25, 2024

Merck KGaA (NYSE: MRK) has entered into a Memorandum of Understanding with the Digital Trust...

Company Drug

GSK’s Arexvy Receives MHLW Approval for Expanded RSV Indication in Japan

Fineline Cube Nov 25, 2024

UK-based pharmaceutical company GlaxoSmithKline (GSK; NYSE: GSK) has announced that Japan’s Ministry of Health, Labour...

Company Drug

China Resources Double-Crane Gets NMPA Approval for Semaglutide Biosimilar Clinical Trial

Fineline Cube Nov 25, 2024

China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced that it has received clinical...

Company Drug

J&J Submits sBLA to FDA for Subcutaneous Tremfya Regimen in Ulcerative Colitis

Fineline Cube Nov 25, 2024

Johnson & Johnson (J&J; NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to...

Company Drug

Servier’s Vorasidenib Approved in Boao Lecheng Medical Zone for Diffuse Gliomas

Fineline Cube Nov 25, 2024

French pharmaceutical company Servier’s Voranigo (vorasidenib), an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor,...

Company Drug

Leads Biolabs’ LBL-024 Earns FDA Orphan Drug Designation for Neuroendocrine Cancer

Fineline Cube Nov 25, 2024

China-based Leads Biolabs Inc. has announced that it has obtained Orphan Drug Designation (ODD) from...

Company Drug

Signet Therapeutics’ SIGX1094 Earns Orphan Drug Designation for Gastric Cancer from FDA

Fineline Cube Nov 25, 2024

China-based Signet Therapeutics has announced that it has received Orphan Drug Designation (ODD) from the...

Posts pagination

1 … 254 255 256 … 660

Recent updates

  • Avistone Biotechnology’s Andatinib Receives China Conditional Approval for EGFR Ex20ins NSCLC
  • GE Healthcare Reports 7.4% Q1 Revenue Growth to $5.1B Driven by Imaging and Pharmaceutical Diagnostics Strength
  • GE Healthcare Restructures Imaging Business with $14.6B AIS Segment and New Executive Leadership
  • AstraZeneca Reports 8% Q1 Revenue Growth to $15.3B Driven by Oncology and Rare Disease Strength
  • BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Avistone Biotechnology’s Andatinib Receives China Conditional Approval for EGFR Ex20ins NSCLC

Company

GE Healthcare Reports 7.4% Q1 Revenue Growth to $5.1B Driven by Imaging and Pharmaceutical Diagnostics Strength

Company

GE Healthcare Restructures Imaging Business with $14.6B AIS Segment and New Executive Leadership

Others

AstraZeneca Reports 8% Q1 Revenue Growth to $15.3B Driven by Oncology and Rare Disease Strength

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.